OmniComm Introduces TrialOne: An Integrated Suite of Web Based Solutions for Phase I Clinic Automation and Management
OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web‐based solution designed to automate the Phase I Clinical Trial Process. TrialOne provides web‐based tools used to recruit study volunteers, schedule screening appointments, collect screening data, directly capture real‐time data, track sample transfers and address the unique requirements of early phase studies. Within each study, real‐time electronic data is captured and validated at the subject’s bedside or at a subject queuing station. Enhanced workflow technology automates sample processing throughout the lab. TrialOne supports a myriad of directly attached biomedical monitoring devices such as the GE Healthcare DINAMAP® family of vital signs monitors and various ECG devices.
TrialOne enables Phase I Clinics to share data with other stakeholders via the internet and provides a flexible ad‐hoc reporting tool to help export and report data in various formats including Adobe® PDF, Microsoft® Excel and Word. Further extensibility of the TrialOne suite via integration to our flagship EDC product, TrialMaster®, using OmniConnect™, our enhanced web services API, and an integrated pharmacy module is planned for release later this year.
“TrialOne is the only available product that handles all aspects of the Phase I process from subject recruitment and clinical wokflow management to laboratory sample management,” said OmniComm’s CTO, Randy Smith.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
